Ambrx Biopharma Inc.
NYSE:AMAM
28 (USD) • At close March 6, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
2022 | 2021 | 2020 | 2019 | |
---|---|---|---|---|
Operating Activities: | ||||
Net Income
| -77.996 | -68.288 | -17.839 | -22.313 |
Depreciation & Amortization
| 1.803 | 2.154 | 1.943 | 2.053 |
Deferred Income Tax
| 0 | 0.513 | 0 | 0.011 |
Stock Based Compensation
| 6.253 | 11.856 | 1.217 | 1.831 |
Change In Working Capital
| -10.621 | 3.64 | -7.375 | 14.176 |
Accounts Receivables
| 0.863 | -0.811 | 0.415 | -0.762 |
Inventory
| 0 | 6.131 | -3.263 | 0.151 |
Accounts Payables
| -1.829 | 2.403 | -3.247 | 3.776 |
Other Working Capital
| -9.655 | -4.083 | -1.28 | 11.011 |
Other Non Cash Items
| 11.886 | 5.485 | 1.478 | 1.477 |
Operating Cash Flow
| -68.675 | -44.64 | -20.576 | -2.765 |
Investing Activities: | ||||
Investments In Property Plant And Equipment
| -1.054 | -3.206 | -0.252 | -0.048 |
Acquisitions Net
| 45.664 | 0 | 0 | 0 |
Purchases Of Investments
| -84.852 | 0 | 0 | 0 |
Sales Maturities Of Investments
| 39.188 | 0 | 0 | 0 |
Other Investing Activites
| -45.664 | 0 | 0 | 0 |
Investing Cash Flow
| -46.718 | -3.206 | -0.252 | -0.048 |
Financing Activities: | ||||
Debt Repayment
| 0 | 0 | 0 | 0 |
Common Stock Issued
| 0 | 148.732 | 0 | 0 |
Common Stock Repurchased
| 0 | 0 | 0 | 0 |
Dividends Paid
| 0 | 0 | 0 | 0 |
Other Financing Activities
| 0.928 | 127.427 | 95.678 | 0 |
Financing Cash Flow
| 0.928 | 127.427 | 95.678 | 0 |
Other Information: | ||||
Effect Of Forex Changes On Cash
| 0 | 0.047 | 0.165 | -0.038 |
Net Change In Cash
| -114.465 | 79.628 | 75.015 | -2.851 |
Cash At End Of Period
| 56.441 | 170.906 | 91.278 | 16.263 |